RDA Financial Network Buys 532 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

RDA Financial Network increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,465 shares of the medical equipment provider’s stock after purchasing an additional 532 shares during the quarter. Intuitive Surgical accounts for 1.2% of RDA Financial Network’s holdings, making the stock its 20th biggest holding. RDA Financial Network’s holdings in Intuitive Surgical were worth $2,895,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of ISRG. Yarbrough Capital LLC bought a new position in Intuitive Surgical in the 2nd quarter valued at $407,000. Keel Point LLC grew its position in Intuitive Surgical by 15.3% in the 2nd quarter. Keel Point LLC now owns 1,219 shares of the medical equipment provider’s stock valued at $417,000 after acquiring an additional 162 shares during the last quarter. Covenant Asset Management LLC grew its position in Intuitive Surgical by 483.1% in the 2nd quarter. Covenant Asset Management LLC now owns 11,994 shares of the medical equipment provider’s stock valued at $4,101,000 after acquiring an additional 9,937 shares during the last quarter. Windsor Group LTD grew its position in Intuitive Surgical by 8.7% in the 2nd quarter. Windsor Group LTD now owns 1,685 shares of the medical equipment provider’s stock valued at $576,000 after acquiring an additional 135 shares during the last quarter. Finally, Burns J W & Co. Inc. NY grew its position in Intuitive Surgical by 0.8% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 6,436 shares of the medical equipment provider’s stock valued at $2,201,000 after acquiring an additional 54 shares during the last quarter. Institutional investors own 82.91% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on ISRG. Citigroup upped their price objective on Intuitive Surgical from $317.00 to $400.00 in a research report on Monday, July 10th. Royal Bank of Canada reissued an “outperform” rating and set a $360.00 price target on shares of Intuitive Surgical in a research report on Thursday, August 17th. Robert W. Baird initiated coverage on Intuitive Surgical in a research report on Tuesday, July 18th. They set an “outperform” rating and a $377.00 price target on the stock. Truist Financial increased their price target on Intuitive Surgical from $347.00 to $400.00 in a research report on Wednesday, July 19th. Finally, Wells Fargo & Company upped their price objective on Intuitive Surgical from $310.00 to $386.00 and gave the stock an “overweight” rating in a research note on Friday, July 21st. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $343.10.

Intuitive Surgical Stock Up 0.6 %

Shares of Intuitive Surgical stock traded up $1.81 on Tuesday, reaching $299.98. The company’s stock had a trading volume of 575,601 shares, compared to its average volume of 1,695,594. The company has a market capitalization of $105.41 billion, a P/E ratio of 74.73, a PEG ratio of 4.15 and a beta of 1.30. Intuitive Surgical, Inc. has a 52-week low of $180.07 and a 52-week high of $358.07. The stock has a 50-day moving average price of $314.56 and a 200-day moving average price of $298.07.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 20th. The medical equipment provider reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.09. Intuitive Surgical had a return on equity of 12.41% and a net margin of 21.38%. The business had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.74 billion. During the same period in the previous year, the business earned $0.85 earnings per share. The business’s revenue was up 15.4% compared to the same quarter last year. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $310.00, for a total transaction of $620,000.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at $7,848,890. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 2,535 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $323.26, for a total transaction of $819,464.10. Following the transaction, the executive vice president now owns 7,259 shares of the company’s stock, valued at $2,346,544.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $310.00, for a total value of $620,000.00. Following the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $7,848,890. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,309 shares of company stock worth $19,649,321. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.